Retrospective cohort study finds a 38% reduction in overall mortality for women with ovarian cancer post-medicaid expansion, highlighting disparities by race and income.
Objective: To evaluate the impact of Medicaid expansion under the Affordable Care Act (ACA) on overall mortality among women diagnosed with ovarian cancer and to assess whether the benefits varied by race/ethnicity and neighborhood income level. Design: Retrospective, population-based cohort study using a difference-in-differences approach with Cox proportional hazards modeling. Setting: Statewide cancer registry data from the United States, 2005 to 2022. Population: A total of 88,024 women aged 40–64 years diagnosed with primary ovarian cancer. Methods: States were categorized as early Medicaid expansion (implemented by 2014) or non-expansion. Adjusted hazard differences were estimated to assess the association between Medicaid expansion and overall mortality. Subgroup and three-way interaction analyses examined disparities by race/ethnicity and ZIP code–level income. Main Outcome Measures: Overall mortality measured as adjusted differences in log hazard ratios pre- and post-expansion. Results: We analyzed a cohort of 88,024 women aged 40–64 years diagnosed with ovarian cancer between 2005 and 2022 Of these, 44,608 (50.7%) were diagnosed before Medicaid expansion and 43,416 (49.3%) after. In expansion states, the proportion of Medicaid beneficiaries increased from 10.2% pre-expansion to 18.0% post-expansion. In contrast, non-expansion states showed only a modest increase (8.2% to 9.0%). Expansion states also saw a sharp decline in the uninsured rate, dropping from 6.3% to 2.5%, while non-expansion states experienced only a minor change (11.2% to 10.2%). Medicaid expansion was associated with a 38.0% reduction in overall mortality compared to non-expansion states [DID]: -0.380, 95% CI: –0.647 to –0.114; p=0.005).Conclusions: Medicaid expansion was associated with increased Medicaid coverage, reduced uninsured rates, and a significant reduction in overall mortality among women with ovarian cancer in the United States.
No takes yet. Share an insight, caveat, or question.
Akinyemi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: